abstract |
The present invention is directed to the use of Bortezomib and/or a pharmaceutically acceptable salt or ester thereof for the manufacture of a medicament for enhancing the expression of membrane proteins on the cell surface. Especially, the invention is directed to the use of Bortezomib for the manufacture of a medicament for the treatment of a disease of condition selected from the group consisting of cystic fibrosis, diabetes insipidus, hypercholesterinaemia and long QT-syndrome-2. |